Use of TPL2 inhibitors, such as a prodrug of tilpisertib, to treat inflammatory bowel disease or ulcerative colitis
Administering a prodrug of Compound A targets the TPL2 kinase pathway to treat IBD, addressing the low efficacy of existing treatments by inhibiting pro-inflammatory cytokines and reducing inflammation.
AU2024400007C1Pending Publication Date: 2026-07-16GILEAD SCIENCES INC
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- GILEAD SCIENCES INC
- Filing Date
- 2024-12-09
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
There is a significant unmet need for safe and effective treatments for inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, as existing treatments have low response and remission rates.
Method used
Administering a prodrug of Compound A, or a pharmaceutically acceptable salt thereof, in specific dosages and administration schedules, along with potential food co-administration, to target the TPL2 kinase pathway and inhibit pro-inflammatory cytokine production.
Benefits of technology
The method effectively treats IBD by inhibiting the TPL2-ERK pathway, reducing inflammation, and achieving clinical benefits such as symptom reduction and disease stabilization.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000001_0000 
Figure 00000081_0000 
Figure 00000082_0000
Abstract
The present disclosure relates generally to methods of using inhibitors of tumor progression locus 2 (TPL2) kinase for treating, stabilizing, or lessening the severity or progression of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and pharmaceutical compositions including TPL2 kinase inhibitors for use in such methods.
Need to check novelty before this filing date? Find Prior Art